Live Breaking News & Updates on Onxeo Sa Euronext

Stay updated with breaking news from Onxeo sa euronext. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Onxeo S.A.: Onxeo: Report on the Extraordinary General Meeting of February 6, 2023

Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX), ("Onxeo" or "the Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor ....

France General , Arthur Rouill , Onis Onxeo , Nicolas Fossiez , Onxeo Sa Euronext , Schwierige Zeiten , Company Group , Regulatory News , Euronext Growth Paris , Extraordinary General Meeting , General Meeting , General Meetings ,

Onxeo S.A.: Onxeo Announces its Financial Agenda for 2023

Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX) (Paris:ALONX), ("Onxeo" or "the Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting ....

France General , Onis Onxeo , Onxeo Sa Euronext , Nicolas Fossiez , Nicolas Merigeau , Company Group , Regulatory News , Euronext Growth Paris ,

ONXEO Provides Update on the Development Program For Its First-in-class Drug Candidate AsiDNATM

ONXEO Provides Update on the Development Program For Its First-in-class Drug Candidate AsiDNATM
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , San Antonio , France General , Shefali Agarwal , Arthur Rouill , Nicolas Fossiez , Onxeo Sa Euronext , Institut Curie , Company Group , Euronext Growth Paris , Next Oncology San , Gustave Roussy Cancer Campus , Grand Paris , Euronext Paris , Strategic Communication ,

Onxeo S.A.: ONXEO Provides Update on the Development Program For Its First-in-class Drug Candidate AsiDNATM

Phase 1b/2 trial of AsiDNATM in combination with olaparib initiated in the United States in recurrent ovarian, breast and metastatic castration-resistant prostate cancer Phase 1b/2 trial (REVOCAN) ....

United States , San Antonio , France General , Shefali Agarwal , Arthur Rouill , Nicolas Fossiez , Onxeo Sa Euronext , Institut Curie , Company Group , Euronext Growth Paris , Next Oncology San , Gustave Roussy Cancer Campus , Grand Paris , Euronext Paris ,

ONXEO Provides Update on the Development Program For Its First-in-class Drug Candidate AsiDNATM

ONXEO Provides Update on the Development Program For Its First-in-class Drug Candidate AsiDNATM
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

San Antonio , United States , France General , Onxeo Sa Euronext , Regulatory News , Euronext Growth Paris , Next Oncology San ,